PERBANDINGAN RESPON STIMULASI OVARIUM TERKENDALIDENGAN PROTOKOL PANJANG ANTARA PASIEN ENDOMETRIOSISPASCA TERAPI GnRH AGONIS 3-6 BULAN DAN TANPA GnRH AGONISSEBELUM FERTILISASI IN VITRO

Background: Administration of GnRH agonist on endometriosis can increased apoptosis and inhibit proliferation of endometrial cells eutopik. How the effectiveness of GnRH agonist for 3-6 months prior to FIV in endometriosis needs tobe studied further. Objective: To determine the effectiveness of GnRH agonists for 3-6 months before FIV output number of mature oocytes, total dose and duration of gonadotropin stimulation with a long protocol stimulation. Methods: This study uses a retrospective observational cohort design. Total population in this study were 60 patients from Klinik Permata Hati Dr RS Sardjito from 2003 to 2011 Results: Total of 60 subjecs of 60 couples undergoing in vitro fertilization were included in the study according to inclusion and exclusion criteria. Ovarian stimulation long after stimulation suppression therapy � 10 days of 10 subjecs (33.3%), length of stimulation <10 days of 20 subjecs (66.7%), whereas those without suppression therapy, the stimulation of long � 10 days and 7 subjecs (23, 3%) and longer stimulation of <10 days of 23 subjecs (76.7%). Number of total gonadotropin dose (� 40 pack) during stimulation without suppressive therapy in group 3 subjecs (10%) and after 5 subjecs of therapy (16.6% ). Fifty-six subjecs (93.3%) with a high number of oocytes (� 3 oocytes) and 4 subjecs (6.7%) by the number of oocytes is low (<3 oocytes). Minimal-mild endometriosis stage (I-II) 27 subjecs (45%), moderate-severe stage (III-IV) 33 subjecs (55%). Group after ovarian suppression therapy prior to clinical FIV give 1.07 times the chance of increasing the number of oocytes than in those without suppression therapy. Conclusion: The number of mature oocytes and the number of total gonadotropin dose was higher in the post-suppression therapy compared with no therapy. Long ovarian stimulation is more elongated in the post-treatment group compared with no therapy.